CN101910197B - 针对铜绿假单胞菌pcrv抗原的抗体 - Google Patents

针对铜绿假单胞菌pcrv抗原的抗体 Download PDF

Info

Publication number
CN101910197B
CN101910197B CN200880124705.7A CN200880124705A CN101910197B CN 101910197 B CN101910197 B CN 101910197B CN 200880124705 A CN200880124705 A CN 200880124705A CN 101910197 B CN101910197 B CN 101910197B
Authority
CN
China
Prior art keywords
region
sequence
antibody
seq
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880124705.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101910197A (zh
Inventor
克里斯托弗·R·贝炳东
肯尼思·鲁尔森
杰弗里·T·亚兰东
马克·百尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humanigen Inc
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of CN101910197A publication Critical patent/CN101910197A/zh
Application granted granted Critical
Publication of CN101910197B publication Critical patent/CN101910197B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200880124705.7A 2007-11-30 2008-12-01 针对铜绿假单胞菌pcrv抗原的抗体 Expired - Fee Related CN101910197B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99167907P 2007-11-30 2007-11-30
US60/991,679 2007-11-30
PCT/US2008/085196 WO2009073631A2 (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Publications (2)

Publication Number Publication Date
CN101910197A CN101910197A (zh) 2010-12-08
CN101910197B true CN101910197B (zh) 2014-09-24

Family

ID=40527381

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880124705.7A Expired - Fee Related CN101910197B (zh) 2007-11-30 2008-12-01 针对铜绿假单胞菌pcrv抗原的抗体

Country Status (15)

Country Link
US (3) US8044181B2 (cg-RX-API-DMAC10.html)
EP (1) EP2220117A2 (cg-RX-API-DMAC10.html)
JP (1) JP5781765B2 (cg-RX-API-DMAC10.html)
KR (1) KR20100097719A (cg-RX-API-DMAC10.html)
CN (1) CN101910197B (cg-RX-API-DMAC10.html)
AU (1) AU2008333985B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0819598A2 (cg-RX-API-DMAC10.html)
CA (1) CA2706732A1 (cg-RX-API-DMAC10.html)
EA (1) EA201000903A1 (cg-RX-API-DMAC10.html)
IL (1) IL206036A0 (cg-RX-API-DMAC10.html)
MX (1) MX2010005871A (cg-RX-API-DMAC10.html)
NZ (1) NZ586357A (cg-RX-API-DMAC10.html)
SG (1) SG186017A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009073631A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201003852B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492243B2 (en) 2016-05-05 2025-12-09 The Trustees Of The University Of Pennsylvania DNA antibody constructs for use against Pseudomonas aeruginosa

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
US9394571B2 (en) * 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) * 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2248826B1 (en) 2008-01-10 2013-06-12 Shionogi&Co., Ltd. Antibody directed against pcrv
US20100272736A1 (en) * 2009-02-04 2010-10-28 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
WO2010104052A1 (ja) 2009-03-11 2010-09-16 塩野義製薬株式会社 抗緑膿菌作用を有するヒト化ＰｃｒＶ抗体
EP2515935A4 (en) * 2009-12-22 2013-08-28 Kalobios Pharmaceuticals Inc METHOD FOR TREATING STAPHYLOCOCCUS INFECTION IN A PATIENT WITH PSEUDOMONAS AERUGINOSA INFECTION WITH LOW PATHOGEN LEVEL
US8512950B2 (en) 2010-07-21 2013-08-20 Saint Louis University Biolayer interferometry measurement of biological targets
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
WO2013070615A1 (en) 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
US20150284450A1 (en) * 2012-11-06 2015-10-08 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
JP6966330B2 (ja) * 2015-05-01 2021-11-17 インヒブルクス，インコーポレイティド Ｉｉｉ型分泌装置標的化分子
JP6807606B2 (ja) 2015-07-16 2021-01-06 インヒブルクス インコーポレイテッド 多価及び多重特異性ｄｒ５結合融合タンパク質
WO2019178085A1 (en) 2018-03-14 2019-09-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
BR112021001683A2 (pt) 2018-08-01 2021-05-04 Cephalon, Inc. anticorpos anti-cxcr2 e usos dos mesmos
CN113966343A (zh) * 2019-06-11 2022-01-21 瑞泽恩制药公司 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
CN114072145B (zh) * 2020-06-01 2024-06-11 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1049488A1 (en) * 1998-11-25 2000-11-08 MCW Research Foundation, Inc. METHOD OF AND COMPOSITIONS FOR IMMUNIZATION WITH THE $i(PSEUDOMONAS) V ANTIGEN
WO2002064161A2 (en) * 2001-01-26 2002-08-22 Mcw Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
CN1788018A (zh) * 2003-05-14 2006-06-14 伯纳生物技术有限公司 铜绿假单胞菌血清型iats o6的脂多糖(lps)特异性的人单克隆抗体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US108565A (en) * 1870-10-25 Improvement in snow-plows
US225552A (en) * 1880-03-16 Disintegrating-mill
US134098A (en) * 1872-12-17 Improvement in gage-cocks
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5219998A (en) * 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
DE69726003T2 (de) 1996-07-16 2004-08-26 Andreas Plückthun Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
DE19918418C1 (de) * 1999-04-23 2000-10-19 Siegfried Mueller Pflanzvorrichtung mit Halterung
AU2001238677A1 (en) 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
US7981843B2 (en) 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
PL2343380T3 (pl) * 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
US20090215165A1 (en) 2005-05-20 2009-08-27 James Rance High-level expression of recombinant antibody in a mammalian host cell
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
KR20080031383A (ko) 2005-07-05 2008-04-08 베이커 메디컬 리서치 인스티튜트 항응고제 및 그의 용도
JP2009531295A (ja) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
US8221751B2 (en) 2006-06-21 2012-07-17 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1049488A1 (en) * 1998-11-25 2000-11-08 MCW Research Foundation, Inc. METHOD OF AND COMPOSITIONS FOR IMMUNIZATION WITH THE $i(PSEUDOMONAS) V ANTIGEN
WO2002064161A2 (en) * 2001-01-26 2002-08-22 Mcw Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
CN1788018A (zh) * 2003-05-14 2006-06-14 伯纳生物技术有限公司 铜绿假单胞菌血清型iats o6的脂多糖(lps)特异性的人单克隆抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Frank D W et al.Generation and Characterization of a Protective Monoclonal Antibody to Pseudomonas aeruginosa PreV.《JOURNAL OF INFECTIOUS DISEASES》.2002,第186卷(第1期),64-73. *
HUMPHREYS DAVID P et al.Alternative antibody Fab" fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.《Protein Engineering Design and Selection》.2007,第20卷(第5期),227-234. *
HUMPHREYSDAVIDPetal.AlternativeantibodyFab"fragmentPEGylationstrategies:combinationofstrongreducingagents disruption of the interchain disulphide bond and disulphide engineering.《Protein Engineering Design and Selection》.2007

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492243B2 (en) 2016-05-05 2025-12-09 The Trustees Of The University Of Pennsylvania DNA antibody constructs for use against Pseudomonas aeruginosa

Also Published As

Publication number Publication date
IL206036A0 (en) 2010-11-30
US8044181B2 (en) 2011-10-25
CA2706732A1 (en) 2009-06-11
SG186017A1 (en) 2012-12-28
US20090191186A1 (en) 2009-07-30
US8877191B2 (en) 2014-11-04
JP5781765B2 (ja) 2015-09-24
WO2009073631A2 (en) 2009-06-11
EP2220117A2 (en) 2010-08-25
ZA201003852B (en) 2014-11-26
EA201000903A1 (ru) 2011-02-28
AU2008333985A1 (en) 2009-06-11
NZ586357A (en) 2012-10-26
US20120020986A1 (en) 2012-01-26
AU2008333985B2 (en) 2015-02-05
JP2011505381A (ja) 2011-02-24
US20150030614A1 (en) 2015-01-29
MX2010005871A (es) 2010-06-09
KR20100097719A (ko) 2010-09-03
WO2009073631A3 (en) 2009-09-24
BRPI0819598A2 (pt) 2017-05-09
CN101910197A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
US8877191B2 (en) Antibodies to the PcrV antigen of Pseudomonas aeruginosa
US12428473B2 (en) Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
JP2011505381A5 (cg-RX-API-DMAC10.html)
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
US20150284450A1 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules
CA2838211C (en) Anti-pseudomonas psl binding molecules and uses thereof
US20100272736A1 (en) Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
HK1201453B (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140924

Termination date: 20161201

CF01 Termination of patent right due to non-payment of annual fee